作者
Y Zhang,Minghao Liu,Peijin Li,Liang Ma,Long Yin,Yunkang Cui,Kai Huang,Wei Li,Xidong Hui,Meixiang Xiang,Chaoliu Dai,Mulei Chen,Jinping Feng,Zeqi Zheng,Yawei Xu,Yihan Chen,Xuejun Jiang,Genshan Ma,Ping Yang,Fang Wang,Xinli Li,Wanqin Jin,Hong Chen,Rutai Hui,Lian Wang,Xiao Hong-yan,Tianshuai Liu,Yubao Zou,Lixin Song
摘要
Summary
Background
The public health burden of cardiomyopathies and competency in their management by health agencies in China are not well understood. Methods
This study adopted a multi-stage sampling method for hospital selection. In the first stage, nationwide tertiary hospital recruitment was performed. As a result, 88 hospitals with the consent of the director of cardiology and access to an established electronic medical records system, were recruited. In the second stage, we sampled 66 hospitals within each geographic-economic stratification through a random sampling process. Data on (1) the outpatient and inpatient visits for cardiomyopathies between 2017 and 2021 and (2) the competency in the management of patients with cardiomyopathies, were collected. The competency of a hospital to provide cardiomyopathy care was evaluated using a specifically devised scale. Findings
The outpatient and inpatient visits for cardiomyopathies increased between 2017 and 2021 by 38.6% and 33.0%, respectively. Most hospitals had basic facilities for cardiomyopathy assessment. However, access to more complex procedures was limited, and the integrated management pathway needs improvement. Only 4 (6.1%) of the 66 participating hospitals met the criteria for being designated as a comprehensive cardiomyopathy center, and only 29 (43.9%) could be classified as a primary cardiomyopathy center. There were significant variations in competency between hospitals with different administrative and economic levels. Interpretation
The health burden of cardiomyopathies has increased significantly between 2017 and 2021 in China. Although most tertiary hospitals in China can offer basic cardiomyopathy care, more advanced facilities are not yet universally available. Moreover, inconsistencies in the management of cardiomyopathies across hospitals due to differing administrative and economic levels warrants a review of the nation allocation of medical resources. Funding
This work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2023-I2M-1-001) and the National High Level Hospital Clinical Research Funding (2022-GSP-GG-17).